Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts’ second-quarter revenue and earnings expectations. Valeant was one of several drugmakers and biotechs to report Thursday morning, including Celgene (CELG), Eli Lilly (LLY), Shire (SHPG) and Bristol-Myers Squibb (BMY) . The Laval, Quebec-based drugmaker said total
Comcast (CMCSA) said Q2 revenue rose 11.3%, topping views, as NBCUniversal sales popped 20.2% on strong box office growth, owing to films “Jurassic World,” “Furious 7” and “Pitch Perfect 2.” NBCU’s filmed entertainment division’s revenue jumped 93% from the year earlier period to $2.26 billion. Comcast’s cable TV business lost 69,000 video subscribers , an improvement over the 144,000 it shed in the June 2014 quarter. However, Comcast added only
Combining superior fundamentals with strong chart action can pinpoint top stock watch candidates such as Gilead Sciences. Today’s Screen Of The Day, Top Fundamentals, features highly rated firms with three-year sales and earnings growth rates of at least 25%, sorted by the biggest estimated earnings-per-share percentage change from a year ago. The list includes three companies that also have the stability of size: drugmaker Gilead Sciences (GILD),